Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RVLP RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About RVL Pharmaceuticals Stock (NASDAQ:RVLP) 30 days 90 days 365 days Advanced Chart Get RVL Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.00▼$0.1952-Week Range N/AVolume63.96 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.Read More… Receive RVLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVLP Stock News HeadlinesUnravel Biosciences Receives FDA Orphan Drug Designation for Vorinostat (RVL-001) as a Treatment for Rett SyndromeMay 28, 2024 | tmcnet.comRaval ICS Ltd.May 17, 2024 | wsj.comHere’s how you could profit from Elon’s NVIDIA partnership"Elon's #1 AI Stock" SET TO SOAR Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world.February 20, 2025 | Behind the Markets (Ad)RVLPQ RVL Pharmaceuticals plcMarch 2, 2024 | seekingalpha.comRVL Pharmaceuticals PLC RVLPQJanuary 11, 2024 | morningstar.comRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For BankruptcyOctober 13, 2023 | marketwatch.comSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | benzinga.comRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be CancelledOctober 12, 2023 | markets.businessinsider.comSee More Headlines RVLP Stock Analysis - Frequently Asked Questions How were RVL Pharmaceuticals' earnings last quarter? RVL Pharmaceuticals plc (NASDAQ:RVLP) posted its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The business earned $9.81 million during the quarter, compared to analysts' expectations of $12.10 million. What other stocks do shareholders of RVL Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that RVL Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Cardiff Oncology (CRDF), Osmotica Pharmaceuticals (OSMT), AbCellera Biologics (ABCL), Amarin (AMRN) and Coda Octopus Group (CODA). Company Calendar Last Earnings3/20/2023Today2/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVLP CUSIPN/A CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees125Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$49.72 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares111,410,000Free Float106,504,000Market CapN/A OptionableOptionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:RVLP) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredBig Tech is Barreling Toward a $17 Trillion ReckoningWhile everyday investors keep piling into names like Nvidia, Apple, and Amazon... the owners of those very com...InvestorPlace | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RVL Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share RVL Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.